Ari J B, Zlotnik M, Oren A, Berlyne G M
Arch Intern Med. 1976 Apr;136(4):449-51.
Ten unselected patients with renal failure casued by amyloidosis associated with FMF were treated by regular hemodialysis therapy from 1969 to 1974. They were compared to age-matched control patients treated by hemodialysis in the same unit during the same period, who were suffering from renal failure caused by other disease. Mortality in FMF and control patients was 30% with no significant difference in mean survival, shunt life, serum albumin or hemoglobin levels between the two groups. There was no significant difference in blood pressure measured predialysis or postdialysis in patients with FMF or in controls. The synthetic ACTH stimulation test showed adequate or elevated adrenocortical function. It is concluded that life can be prolonged up to 3 1/2 years by hemodialysis in renal failure caused by amyloidosis complicating FMF, and that renal failure casued by FMF is not a contraindication to regular hemodialysis therapy.
1969年至1974年期间,对10例因与家族性地中海热(FMF)相关的淀粉样变性导致肾衰竭的未选患者进行了常规血液透析治疗。将他们与同期在同一科室接受血液透析治疗的年龄匹配的对照患者进行比较,这些对照患者患有由其他疾病引起的肾衰竭。FMF患者和对照患者的死亡率均为30%,两组之间的平均生存期、分流使用寿命、血清白蛋白或血红蛋白水平无显著差异。FMF患者或对照患者透析前或透析后的血压测量无显著差异。合成促肾上腺皮质激素刺激试验显示肾上腺皮质功能正常或升高。得出的结论是,对于因淀粉样变性并发FMF导致的肾衰竭,通过血液透析可将生命延长至3.5年,并且FMF导致的肾衰竭并非常规血液透析治疗的禁忌证。